117
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Optimisation of methadone treatment in a group of patients on a mephedrone binge and dependent on many psychoactive substances

, , &
Pages 38-42 | Received 01 Jul 2019, Accepted 15 Oct 2019, Published online: 30 Oct 2019

References

  • Alexandrescu, L. (2017). NPS and the methadone queue: Spillages of space and time. International Journal of Drug Policy, 40, 50–56. doi:10.1016/j.drugpo.2016.09.009
  • Aunno, D., Pollack, H. A., Frimpong, J. A., & Wutchiett, D. (2014). Evidence-based treatment for opioid disorders: A 23-year national study of methadone dose levels. Journal of Substance Abuse Treatment, 47, 245–250. doi:10.1016/j.jsat.2017.05.001
  • Dinis-Oliveira, R. J. (2016). Metabolomics of methadone: Clinical and forensic toxicological implications and variability of dose response. Drug Metabolism Reviews, 48, 568–576. doi:10.1080/03602532.2016.1192642
  • Hockenhull, J., Murphy, K. G., & Paterson, S. (2016). Mephedrone use is increasing in London. The Lancet, 387, 1719–1720. doi:10.1016/S0140-6736(16)30258-6
  • Jeanne, K. M., Borg, L., Ducat, E., & Ray, B. (2010). Pharmacotherapy in the treatment of addiction: Methadone. Journal of Addictive Diseases, 29, 200–216. doi:10.1080/10550881003684798
  • Käferstein, H., Sticht, G., & Madea, B. (2013). Chlorprothixene in bodies after exhumation. Forensic Science International, 229, e30–e34. doi:10.1016/j.forsciint.2013.03.051
  • Karila, L., Billieux, J., Benyamina, A., Lancon, C., & Cottencin, O. (2016). The effects and risks associated to mephedrone and methylone in humans: A review of the preliminary evidences. Brain Research Bulletin, 126, 61–67. doi:10.1016/j.brainresbull.2016.03.005
  • Ključević, Ž., Benzon, B., Ključević, N., Veršić Bratinčević, M., & Sutlović, D. (2018). Liver damage indices as a tool for modifying methadone maintenance treatment: A cross-sectional study. Croatian Medical Journal, 59, 298–306. doi:10.3325/cmj.2018.59.298
  • Liu, J., Cai, W., Liu, W., Han, B., Chang, J., & Yang, Y. (2012). Modulation of liver L-γ-glutamyl-L-cysteinylglycine homeostasis by N-acetyl-glucosamine-thiazolidine-4(R)-carboxylic acid in mice. The American Journal of the Medical Sciences, 343, 310–315. doi:10.1097/MAJ.0b013e31822b02f4
  • Mailman, R. B., & Murthy, V. (2010). Third generation antipsychotic drugs: Partial agonism or receptor functional selectivity? Current Pharmaceutical Design, 16, 488–501. doi:10.2174/138161210790361461
  • Önen Bayram, F. E., Sipahi, H., Acar, E. T., Kahveci Ulugöl, R., Buran, K., & Hülya, A. (2016). The cysteine releasing pattern of some antioxidant thiazolidine-4-carboxylic acids. European Journal of Medicinal Chemistry, 23, 337–344. doi:10.1016/j.ejmech.2016.03.019
  • Ordak, M., Nasierowski, T., & Muszynska, E. (2018). The growing problem of mephedrone use in Warsaw, Poland, 2010–18. The Lancet Psychiatry, 5, 787. doi:10.1016/S2215-0366(18)30305-5
  • Ordak, M., Nasierowski, T., & Muszynska, E. (2019). The problem of poly-pharmacotherapy in patients on a mephedrone binge. Pharmacological Research, 143, 204. doi:10.1016/j.phrs.2019.04.003
  • Papaseit, E., Pérez-Mañá, C., Mateus, J.-A., Pujadas, M., Fonseca, F., Torrens, M., … Farré, M. (2016). Human pharmacology of mephedrone in comparison with MDMA. Neuropsychopharmacology, 41, 2704–2713. doi:10.1038/npp.2016.75
  • Salaspuro, V. (2007). Pharmacological treatments and strategies for reducing oral and intestinal acetaldehyde. Novartis Foundation Symposium, 285, 145–153.
  • Salsitz, E., & Wiegand, T. (2016). Pharmacotherapy of opioid addiction: “Putting a Real Face on a False Demon”. Journal of Medical Toxicology, 12, 58–63. doi:10.1007/s13181-015-0517-5
  • Scherbaum, N., Kluwig, J., Specka, M., Krause, D., Merget, B., Finkbeiner, T., & Gastpar, M. (2005). Group psychotherapy for opiate addicts in methadone maintenance treatment—A controlled trial. European Addiction Research, 11, 163–171. doi:10.1159/000086397
  • Sohrabian, H., Sahraei, H., Hatef, B., & Meftahi, G. H. (2017). An evaluation of the role of OTC [(−)-2-oxo-4-thiazolidinecarboxylic acid] in acquisition and expression of morphine dependence in male NMRI mice. Journal of Babol University of Medical Sciences, 19, 61–67.
  • Tracy, D. K., Wood, D. M., & Baumeister, D. (2017). Novel psychoactive substances: TYPES, mechanisms of action, and effects. BMJ, 356, i6848.
  • Winstock, A., Mitcheson, L., Ramsey, J., Davies, S., Puchnarewicz, M., & Marsden, J. (2011). Mephedrone: Use, subjective effects and health risks. Addiction, 106, 1991–1996. doi:10.1111/j.1360-0443.2011.03502.x

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.